Biostax (BTAX) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 12, 2016
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	1,559,356
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		220,989,542
Trading Symbol	IMUN
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 64,289	$ 23,149
Accounts receivable	2,661	16,197
Prepaids and other current assets	11,272
Total current assets	78,222	39,346
Fixed Assets:
Computer equipment, net of accumulated depreciation of $7,312 and $6,331 respectively	701	1,682
Deposits	200	200
Total assets	79,123	41,228
Current Liabilities:
Accounts payable	1,517,788	1,924,672
Accrued liabilities	2,030,559	1,281,039
Current portion of notes payable	3,457,436	2,793,701
Total current liabilities	7,005,783	5,999,412
Non-current liabilities:
Notes payable, less current portion
Total non-current liabilities
Total liabilities	7,005,783	5,999,412
Commitments and Contingencies (Note 10)
Stockholders' Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 214,447,611 and 174,850,047 shares issued and outstanding respectively	21,445	17,485
Additional paid in capital	354,333,473	343,434,786
Stock issuances due	1,275,838	1,140,303
Prepaid services	(1,983,024)	(660,417)
Accumulated deficit	(358,319,891)	(347,789,889)
Deficit attributable to common shareholders	(4,672,159)	(3,857,732)
Non-controlling interest	(2,254,501)	(2,100,452)
Total stockholders' deficit	(6,926,660)	(5,958,184)
Total liabilities and stockholders' deficit	$ 79,123	$ 41,228

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 7,312	$ 6,331
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	214,447,611	174,850,047
Common Stock, Shares Outstanding	214,447,611	174,850,047

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Revenues, net		$ 5,648	$ 3,463	$ 7,718
Operating expenses
Selling, general and administrative	893,917	443,585	1,833,258	845,572
Research and development expense	67,262	414,492	48,420	591,650
Stock issued for services G&A	1,194,761	1,450,334	3,178,598	3,611,893
Warrant valuation	490,355		2,568,554
Depreciation and amortization expense	434	148,726	981	297,452
Total operating expenses	2,646,729	2,457,137	7,629,811	5,346,567
Loss from operations	(2,646,729)	(2,451,489)	(7,626,348)	(5,338,849)
Other income (expense):
Interest expense	(1,051,576)	(50,711)	(1,353,020)	(68,757)
Loss on settlement of debt	(340,343)	(88,445)	(1,704,683)	(88,445)
Total other income (expense)	(1,391,919)	(139,156)	(3,057,703)	(157,202)
Net (loss)	(4,038,648)	(2,590,645)	(10,684,051)	(5,496,051)
Net (loss) attributable to non-controlling interest	(109,929)	(138,891)	(154,049)	(262,956)
Net (loss) attributable to common shareholders	$ (3,928,719)	$ (2,451,754)	$ (10,530,002)	$ (5,233,095)
Basic and diluted loss per share attributable to common shareholders	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.04)
Weighted average number of shares outstanding	207,229,469	147,387,763	199,076,428	142,563,007

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2016 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock to Be Issued [Member]	Prepaid Service [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2015	$ 17,485	$ 343,434,786	$ 1,140,303	$ (660,417)	$ (347,789,889)	$ (2,100,452)	$ (5,958,184)
Balance, shares at Dec. 31, 2015	174,850,047
Issuance of common stock for prepaid services	$ 2,349	4,518,321	(19,466)	(2,862,535)			1,638,669
Issuance of common stock for prepaid services, shares	23,493,000
Amortization of prepaid services				1,539,928			1,539,928
Issuance of common stock for interest expense	$ 90	148,910					$ 149,000
Issuance of common stock for interest expense,shares	896,296						896,296
Issuance of common stock for legal fees	$ 15	22,485					$ 22,500
Issuance of common stock for legal fees,shares	150,000
Issuance of common stock in exchange for debt	$ 1,444	2,907,814	155,001				3,064,259
Issuance of common stock in exchange for debt, shares	14,433,268
Debt discount		682,665					682,665
Issuance of common stock for cash and exercise of warrants	$ 62	49,938					50,000
Issuance of common stock for cash and exercise of warrants, shares	625,000
Issuance and modification of stock warrants		2,568,554					2,568,554
Net loss					(10,530,002)	(154,049)	(10,684,051)
Balance at Jun. 30, 2016	$ 21,445	$ 354,333,473	$ 1,275,838	$ (1,983,024)	$ (358,319,891)	$ (2,254,501)	$ (6,926,660)
Balance, shares at Jun. 30, 2016	214,447,611

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (10,684,051)	$ (5,496,051)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	981	1,335
Amortization		296,117
Stock issued, and amortization of stock issued, for prepaid services	1,539,928	3,530,894
Loss on settlement of debt	1,704,683	600,562
Stock issued for services	1,661,169
Stock issued for legal settlement		81,000
Amortization of debt discount	385,288
Stock warrant expense	2,568,554
Stock (returned) issued for donation
Stock issued for interest	149,000
Changes in operating assets and liabilities:
Accounts payable	104,131	(158,931)
Accounts receivable	13,536	(7,718)
Accrued liabilities	1,168,324	(112,285)
Prepaid expenses and deposits	(11,272)
Net cash used in operating activities	(1,399,729)	(1,265,077)
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants	50,000	152,000
Proceeds from issuance of notes payable	1,390,869	943,475
Net cash provided by financing activities	1,440,869	1,095,475
Net increase (decrease) in cash	41,140	(169,602)
Cash and cash equivalents at beginning of period	23,149	191,987
Cash and cash equivalents at end of period	64,289	22,385
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	10,317	7,500
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt and accrued interest to common stock	3,064,259	600,562
Non-controlling interest	$ 154,049	$ 262,956

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). Today, the Company is focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS, malaria, and opportunistic infections arising from their treatment, and commercializing affordable, non-toxic therapies in Africa, to be followed by Asia and South America, and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the body’s immune system. The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a new subsidiary, Cytocom Inc. (“Cytocom”). Cytocom is a clinical-stage pharmaceutical company focused on the development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, and is responsible for the development of the Company’s patented therapies under the auspices of the FDA and EMA. In December 2014, the Company finalized the distribution of common stock of Cytocom to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union). The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom during drug development. On December 8, 2014, the number of Cytocom shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the transaction, Cytocom issued 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% equity interest in Cytocom on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. At June 30, 2016, the Company’s equity interest had been further reduced to 41%, by subsequent issuances of Cytocom common stock to shareholders in settlement of notes payable. In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. Going Concern The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2015 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2016 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. The Company experienced a net loss from operations of $(7,626,348) and used cash and cash equivalents from operations in the amount of $1,399,729) during the six months ended June 30, 2016, resulting in stockholders equity of $(6,926,660) at June 30, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2015 (including the notes thereto) set forth in Form 10-K/A. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2015. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2016, the Company has no uninsured cash balances. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Fair Value Measurements The ASC Topic 820, Fair Value Measurements, Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2016 and June 30, 2015 was $434 and $667, respectively. Intangible Assets Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. At the end of 2015, the Company determined that the unamortized carrying amount recorded for the acquisition of licenses and patents related to LDN were impaired, and recorded an impairment loss of $5,226,352. In 2014, the Company determined that the carrying amount recoded for the acquisition of licenses and patents related to MENK were impaired, and recorded an impairment loss of $9,908,477. During the quarters ended June 30, 2016 and June 30, 2015, the Company did not capitalize any costs to acquire and/or develop the Company’s product licenses and patents. (See Note 10). Amortization expense for the quarters ended June 30, 2016 and June 30, 2015 was $0 and $148,059, respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows FASB ASC Topic 740, “Income Taxes,” The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015 and June 30, 2016, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. At the end of the quarters ended June 30, 2016 and June 30, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions. Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair market value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees Non-controlling Interest In accordance with ASC 810, Consolidation Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the three months ended June 30, For the six months ended June 30, 2016 2015 2016 2015 Net loss per share: Numerator Net loss $ (4,038,648 ) $ (2,590,645 ) $ (10,684,051 ) $ (5,496,051 ) Net loss attributed to Common stockholders $ (3,928,719 ) $ (2,451,754 ) $ (10,530,002 ) $ (5,233,095 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 207,229,469 147,387,763 199,076,428 142,563,007 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.02 ) $ (0.05 ) $ (0.04 ) The Company’s potential dilutive securities which include stock, stock warrants and convertible debt have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: As of June 30, 2016 2015 Warrants to purchase Common stock 32,748,908 9,372,750 32,748,908 9,372,750 Recent Accounting Standards During the quarter ended June 30, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2016
Fixed Assets:
Property and Equipment	3. Property and Equipment June 30, 2016 December 31, 2015 Property and equipment: Computer equipment $ 8,013 $ 8,013 Less accumulated depreciation (7,312 ) (6,331 ) Property and equipment, net $ 701 $ 1,682 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Liabilities	4. Accrued Liabilities Accrued expenses and other liabilities consist of the following: June 30, 2016 December 31, 2015 (in thousands) Accrued payroll to officers and others $ 1,013 $ 758 Accrued interest and penalties - notes payable 843 237 Accrued legal settlements 174 282 Other accrued liabilities 1 4 Total accrued expenses and other liabilities $ 2,031 $ 1,281

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable Notes payable consist of the following: June 30, 2016 December 31, 2015 Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at June 30, 2015, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. One of these notes ($60,000), together with interest accrued on the note to March 31, 2016 ($8,183), was converted to equity on August 4, 2016 for 852,292 shares of the Company’s common stock. In addition, the note holder agreed to waive future payments of his pro-rata share of two percent of the Company’s gross receipts for sales of Lodonal TM 346,000 711,500 Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. - 7,000 Promissory notes issued between May 1, 2015 and June 30, 2016, and maturing between June 14, 2015 and June 30, 2017. Lenders on loans aggregating $834,927 earn interest at rates between 10% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. One of these notes ($278,933), together with interest accrued to April 1, 2016 ($18,888), was converted on August 4, 2016 to 3,722,013 shares of the Company’s common stock. Notes aggregating $223,500 were in default at June 30, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. 1,033,427 669,933 Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. This note, together with interest accrued to April 1, 2016 ($4,778), was converted on August 4, 2016 to 2,559,725 shares of the Company’s common stock. 200,000 200,000 Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. One of these notes ($350,000), together with interest accrued on the note to March 31, 2016 ($11,304), was converted to equity on August 4, 2016 for 4,516,302 shares of the Company’s common stock. 775,000 800,000 Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $5,000 per day. 100,000 130,000 Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016. This note, together with interest accrued on the note to July 19, 2016 ($10,536), was converted to equity on July 19, 2016 for 1,235,356 shares of the Company’s common stock. 175,268 175,268 Promissory notes issued between April 6, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. 1,161,250 - Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. One of these notes ($50,000), together with interest accrued on the note to July 19, 2016 ($3,479), was converted to equity on July 19, 2016 for 1,069,589 shares of the Company’s common stock. 162,737 - Less: Original issue discounts on notes payable and warrants issued with notes. (596,246 ) - Total 3,457,436 2,793,701 Less: Current Portion $ (3,457,436 ) $ (2,793,701 ) Long-Term debt, less current portion $ - $ - As of June 30, 2016, the Company had accrued $843 in unpaid interest, compared to $236,671 as of December 31, 2015. These amounts included default of penalties of $581,324 at June 30, 2016, compared to $18,954 at December 31, 2015. During the six months ended June 30, 2016, 896,296 shares with a fair value of $149,000 were issued by the Company for interest expense under promissory notes.

Capital Structure - Common Stoc

Capital Structure - Common Stock and Common Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Capital Structure - Common Stock and Common Stock Purchase Warrants	6. Capital Structure—Common Stock and Common Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of June 30, 2016 and 2015, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of June 30, 2016, the Company had 214,447,611 shares of common stock outstanding, and 174,850,047 outstanding as of December 31, 2015. Stock Warrants In the quarter ended June 30, 2016, the Company issued 23,654,908 warrants. In the quarter ended June 30, 2016, the Company extended to December 31, 2018 the maturity dates on 5,006,666 existing warrants that were originally issued with expiration dates between July 25, 2016 to December 17, 2018. These warrants were originally issued with 3 to 5 year terms, with exercise prices ranging between $0.75 and $1.00. There were no modifications of the terms of any warrants issued by the Company in the quarter ended June 30, 2015. Following is a summary of outstanding stock warrants at June 30, 2016 and activity during the six months then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2015 9,131,500 $ 0.07-15.00 $ 1.47 Issued in 2016 23,654,908 $ 0.14-2.00 $ 0.32 Expired (37,500 ) $ 5.00 $ 5.00 Exercised (0 ) $ 0 $ 0 Warrants as of June 30, 2016 32,748,908 $ 0.07-15.00 $ 0.54 Summary of outstanding warrants as of June 30, 2016: Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2016 125,000 $ 5.00 .25 Fourth Quarter 2017 350,000 1.50-9.00 1.50 First Quarter 2018 127,500 $ 15.00 1.75 Second Quarter 2018 33,334 $ 15.00 2.00 Third Quarter 2018 250,000 $ 1.50 2.25 Fourth Quarter 2018 6,089,166 $ 1.00-1.50 2.50 First Quarter 2019 4,024,000 $ 0.50-2.00 2.75 Second Quarter 2019 135,000 $ 0.07–0.23 3.00 Third Quarter 2019 260,000 $ 0.50-1.50 3.25 Fourth Quarter 2019 400,000 $ 0.14 3.50 Second Quarter 2020 300,000 $ 0.50 4.00 Third Quarter 2020 1,000,000 $ 0.20 4.25 Fourth Quarter 2020 12,650,000 $ 0.20 4.50 First Quarter 2021 7,004,908 $ 0.10-0.20 4.75

Stock Compensation

Stock Compensation	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stock Compensation	7. Stock Compensation Shares Issued for Services During the six months ended June 30, 2016 and 2015, the Company issued 23,643,000 and 10,239,170 shares of common stock respectively for consulting fees. The Company valued these shares at $4,543,170 and $1,810,876 respectively, based upon the fair value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods which are typically between 12 and 24 months. The amortization of prepaid services totaled $1,539,928 and $3,530,894 for the six months ended June 30, 2016 and 2015.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	8. Income Taxes Results of Operations There was no income tax expense reflected in the results of operations for the quarters ended June 30, 2016 and 2015 because the Company incurred a net loss in both quarters. The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2015. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. The Company’s effective tax rate for fiscal years 2015 and 2013 was 0%. The Company’s tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year. As of December 31, 2015, the Company has estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $66,500,000, which will expire in 2032-2035.

Licenses and Supply Agreements

Licenses and Supply Agreements	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Licenses and Supply Agreements	9. Licenses and Supply Agreements Patent and Subsidiary Acquisition The Company has not entered into any new licenses or supply agreements during quarter ending June 30, 2016. All prior licenses, supply agreements, and patents remain unchanged from the prior quarter.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Except as described below, t Distribution of Lodonal TM Through its wholly-owned subsidiary, TNI BioTech International, Ltd., in December 2015 the Company completed a 90-day bridging trial for the treatment of patients with HIV/AIDS. The trial consisted of a total of 150 patients of both genders between the ages of 18-60, each of whom was infected HIV/AIDS. The primary objective of this bridging trial was to confirm that Lodonal TM TM In April 2016, the Company announced that Nigeria’s National Agency for Food and Drug Administration and Control (“NAFDAC”) had approved its Lodonal TM TM Contract Manufacturing Agreements On May 16, 2016, the Company entered into an agreement with Complete Pharmacy and Medical Solutions, LLC (“CPMS”) to compound, package and distribute the LDN tablets, capsules and/or creams in the United States. The initial term of the agreement is three years, with the option to renew for an additional year. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach, provided however that if the Company terminates the contract to reimburse CPMS for all unused packaging materials for the LDN, which unused packaging materials CPMS will provide to IMUN. If CPMS does not receive and ship at least 1,000 orders (prescriptions), the Company will be required to reimburse CPMS for 100% of the “ramp up costs” (defined as all costs and expenses of labor and materials related to the testing, and required FDA and other governmental documentation/approvals of test data) of providing and producing the LDN, even where the Company cancels/terminates the Agreement, which provision shall survive the cancellation/termination of this Agreement. Operating Leases At June 30, 2016, the Company was a party to an agreement to lease office space in Orlando, Florida. Rent expense for the quarters ended June 30, 2016 and 2015 was $4,011 and $18,319, respectively. Legal Proceedings None.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events In July 2016, the Company amended the terms of a $100,000 note payable that was due of March 29, 2016. In accordance with the amendment, the amount of the note was increased to $130,000, the maturity date was extended to July 31, 2016, and the number of Company shares due on the original note was increased from 100,000 to 225,000. The note is in default. Between July 1, 2016 and August 12, 2016, the Company repaid or amended the following notes payable through conversions of obligations into shares of the Company’s common stock as follows: ● A note payable to an officer ($50,000), together with interest accrued on the note to July 14, 2016 ($3,479), was converted to equity on July 19, 2016 for 1,069,589 shares of the Company’s common stock. ● A note payable ($175,267), together with interest accrued on the note to June 30, 2016 ($10,536), was converted to equity on July 19, 2016 for 1,235,356 shares of the Company’s common stock. ● A note payable by Cytocom ($350,000), together with interest accrued on the note to April 1, 2016 ($11,304), was converted to equity on August 4, 2016 for 4,516,302 shares of the Company’s common stock . ● A note payable ($60,000), together with interest accrued on the note to April 1, 2016 ($8,183), was converted to equity on August 4, 2016 for 852,292 shares of the Company’s common stock. In addition, the note holder agreed to waive future payments of his pro-rata share of two percent of the Company’s gross receipts for sales of Lodonal TM ● Two notes payable ($200,000 and $278,933), together with interest accrued on the note to April 1, 2016 ($23,606), were converted to equity on August 4, 2016 for 6,281,738 shares of the Company’s common stock. In July 2016, the Company issued promissory notes as follows: ● A note payable, dated July 5, 2016, for $50,000, paying interest at 6% per month, and maturing on October 5, 2016. ● A note payable, issued on July 7, 2016, for $180,000, maturing on March 07, 2017. The Company received $150,000 upon issuance of the note. The Company must apply the consideration towards obtaining governmental approvals for the use and sale of Lodonal™ in Malawi, Africa. If the Company fails to repay the note at maturity, the holder has the right, at any time after the maturity date, at its election, to convert all or part of the outstanding and unpaid principal and accrued into shares common stock of the Company, in number equal to the dollar conversion amount divided by the lesser of $0.15 or 80% of the lowest trade price in the 25 trading days prior to the conversion. In July 2016, the Company issued shares of the Company’s common stock for services as follows: ● 1,000,000 shares issued on July 14, 2016 as a bonus under an agreement to provide investor relations services. ● 200,000 shares issued on July 19, 2016 for services related to the trial of Lodonal TM Between July 1, 2016 and August 12, 2016, the Company issued warrants as follows: ● A warrant issued to Paul Akin, director, on July 1, 2016, for services as director, to purchase 1,000,000 shares of the Company’s common stock at $0.15 per share. The warrant expires on June 30, 2021. ● A warrant issued to Nicholas Plotnikoff, director, on August 5, 2016, as payment for services previously rendered as director, to purchase 150,000 shares of the Company’s common stock at $0.20 per share. The warrant expires on July 28, 2021. As of August 12, 2016, the Company had outstanding 220,989,592 shares of common stock.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Summary Of Significant Accounting Policies Policies
Basis of Presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2015 (including the notes thereto) set forth in Form 10-K/A. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2015. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At June 30, 2016, the Company has no uninsured cash balances.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments”
Fair Value Measurements	Fair Value Measurements The ASC Topic 820, Fair Value Measurements,
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the quarters ended June 30, 2016 and June 30, 2015 was $434 and $667, respectively.
Intangible Assets	Intangible Assets Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value. At the end of 2015, the Company determined that the unamortized carrying amount recorded for the acquisition of licenses and patents related to LDN were impaired, and recorded an impairment loss of $5,226,352. In 2014, the Company determined that the carrying amount recoded for the acquisition of licenses and patents related to MENK were impaired, and recorded an impairment loss of $9,908,477. During the quarters ended June 30, 2016 and June 30, 2015, the Company did not capitalize any costs to acquire and/or develop the Company’s product licenses and patents. (See Note 10). Amortization expense for the quarters ended June 30, 2016 and June 30, 2015 was $0 and $148,059, respectively.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows FASB ASC Topic 740, “Income Taxes,” The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2015 and June 30, 2016, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. At the end of the quarters ended June 30, 2016 and June 30, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair market value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees
Non-controlling Interest	Non-controlling Interest In accordance with ASC 810, Consolidation
Net Loss Per Share	Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic and diluted net loss per share follows: For the three months ended June 30, For the six months ended June 30, 2016 2015 2016 2015 Net loss per share: Numerator Net loss $ (4,038,648 ) $ (2,590,645 ) $ (10,684,051 ) $ (5,496,051 ) Net loss attributed to Common stockholders $ (3,928,719 ) $ (2,451,754 ) $ (10,530,002 ) $ (5,233,095 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 207,229,469 147,387,763 199,076,428 142,563,007 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.02 ) $ (0.05 ) $ (0.04 ) The Company’s potential dilutive securities which include stock, stock warrants and convertible debt have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average Common stock outstanding used to calculate both basic and diluted net loss per share is the same. The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: As of June 30, 2016 2015 Warrants to purchase Common stock 32,748,908 9,372,750 32,748,908 9,372,750
Recent Accounting Standards	Recent Accounting Standards During the quarter ended June 30, 2016, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2015, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2016
Summary Of Significant Accounting Policies Tables
Schedule of Basic and Diluted Net Loss Per Share	A calculation of basic and diluted net loss per share follows: For the three months ended June 30, For the six months ended June 30, 2016 2015 2016 2015 Net loss per share: Numerator Net loss $ (4,038,648 ) $ (2,590,645 ) $ (10,684,051 ) $ (5,496,051 ) Net loss attributed to Common stockholders $ (3,928,719 ) $ (2,451,754 ) $ (10,530,002 ) $ (5,233,095 ) Denominator Weighted-average common shares outstanding— Denominator for basic and diluted net loss per share 207,229,469 147,387,763 199,076,428 142,563,007 Basic and diluted net loss per share attributed to common stockholders $ (0.02 ) $ (0.02 ) $ (0.05 ) $ (0.04 )
Schedule of Antidilutive Securities	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as the effect of including such securities would be antidilutive: As of June 30, 2016 2015 Warrants to purchase Common stock 32,748,908 9,372,750 32,748,908 9,372,750

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Property And Equipment Tables
Schedule of Property and Equipment	June 30, 2016 December 31, 2015 Property and equipment: Computer equipment $ 8,013 $ 8,013 Less accumulated depreciation (7,312 ) (6,331 ) Property and equipment, net $ 701 $ 1,682

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities Tables
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: June 30, 2016 December 31, 2015 (in thousands) Accrued payroll to officers and others $ 1,013 $ 758 Accrued interest and penalties - notes payable 843 237 Accrued legal settlements 174 282 Other accrued liabilities 1 4 Total accrued expenses and other liabilities $ 2,031 $ 1,281

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Payable Tables
Schedule of Notes Payable	Notes payable consist of the following: June 30, 2016 December 31, 2015 Promissory note issued July 29, 2014 to Ira Gaines. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and September 30, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. Notes aggregating $346,000 were in default at June 30, 2015, as the Company was unable to pay installments on those notes on their due dates. No demands for repayment have been made by the lenders. One of these notes ($60,000), together with interest accrued on the note to March 31, 2016 ($8,183), was converted to equity on August 4, 2016 for 852,292 shares of the Company’s common stock. In addition, the note holder agreed to waive future payments of his pro-rata share of two percent of the Company’s gross receipts for sales of Lodonal TM 346,000 711,500 Promissory note issued October 17, 2014 to Roger Bozarth. The note matures on October 17, 2015 and earns interest at a rate of 2% per annum. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. - 7,000 Promissory notes issued between May 1, 2015 and June 30, 2016, and maturing between June 14, 2015 and June 30, 2017. Lenders on loans aggregating $834,927 earn interest at rates between 10% and 18% per annum. On loans aggregating $198,500, interest is payable in a fixed amount not tied to a specific interest rate. One of these notes ($278,933), together with interest accrued to April 1, 2016 ($18,888), was converted on August 4, 2016 to 3,722,013 shares of the Company’s common stock. Notes aggregating $223,500 were in default at June 30, 2016, as the Company was unable to repay those notes on their due dates. No demands for repayment have been made by the lenders. 1,033,427 669,933 Promissory note issued January 26, 2015 to Robert J. Dailey. The note is senior to, and has priority in right of payment over, all indebtedness of the Company. The note earns interest at a rate of 2% per annum and was due on July 30, 2015. The Company was unable to repay the note at maturity and the note is in default, although no demand for repayment has been made by the lender. This note, together with interest accrued to April 1, 2016 ($4,778), was converted on August 4, 2016 to 2,559,725 shares of the Company’s common stock. 200,000 200,000 Promissory notes issued by Cytocom Inc. between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on September 30, 2016. One of these notes ($350,000), together with interest accrued on the note to March 31, 2016 ($11,304), was converted to equity on August 4, 2016 for 4,516,302 shares of the Company’s common stock. 775,000 800,000 Promissory notes issued in December 2015. Lenders earn interest at a rate of 10% per month. Notes are repayable on March 9, 2016. The Company was unable to repay the note at maturity and the note is in default. The Company is obligated to pay late-payment penalties totaling $5,000 per day. 100,000 130,000 Promissory note issued November 24, 2015 as settlement of amounts owing to a law firm. The Lender earns interest at the rate of 10% per annum. The note is repayable in full on December 1, 2016. This note, together with interest accrued on the note to July 19, 2016 ($10,536), was converted to equity on July 19, 2016 for 1,235,356 shares of the Company’s common stock. 175,268 175,268 Promissory notes issued between April 6, 2016 and June 2, 2016 that mature between October 1, 2016 and January 31, 2017, and include stock conversion features, warrants and original issue debt discounts. 1,161,250 - Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. One of these notes ($50,000), together with interest accrued on the note to July 19, 2016 ($3,479), was converted to equity on July 19, 2016 for 1,069,589 shares of the Company’s common stock. 162,737 - Less: Original issue discounts on notes payable and warrants issued with notes. (596,246 ) - Total 3,457,436 2,793,701 Less: Current Portion $ (3,457,436 ) $ (2,793,701 ) Long-Term debt, less current portion $ - $ - As of June 30, 2016, the Company had accrued $843 in unpaid interest, compared to $236,671 as of December 31, 2015. These amounts included default of penalties of $581,324 at June 30, 2016, compared to $18,954 at December 31, 2015. During the six months ended June 30, 2016, 896,296 shares with a fair value of $149,000 were issued by the Company for interest expense under promissory notes.

Capital Structure - Common St23

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Capital Structure - Common Stock And Common Stock Purchase Warrants Tables
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at June 30, 2016 and activity during the six months then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2015 9,131,500 $ 0.07-15.00 $ 1.47 Issued in 2016 23,654,908 $ 0.14-2.00 $ 0.32 Expired (37,500 ) $ 5.00 $ 5.00 Exercised (0 ) $ 0 $ 0 Warrants as of June 30, 2016 32,748,908 $ 0.07-15.00 $ 0.54
Summary of Outstanding Warrants	Summary of outstanding warrants as of June 30, 2016: Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2016 125,000 $ 5.00 .25 Fourth Quarter 2017 350,000 1.50-9.00 1.50 First Quarter 2018 127,500 $ 15.00 1.75 Second Quarter 2018 33,334 $ 15.00 2.00 Third Quarter 2018 250,000 $ 1.50 2.25 Fourth Quarter 2018 6,089,166 $ 1.00-1.50 2.50 First Quarter 2019 4,024,000 $ 0.50-2.00 2.75 Second Quarter 2019 135,000 $ 0.07–0.23 3.00 Third Quarter 2019 260,000 $ 0.50-1.50 3.25 Fourth Quarter 2019 400,000 $ 0.14 3.50 Second Quarter 2020 300,000 $ 0.50 4.00 Third Quarter 2020 1,000,000 $ 0.20 4.25 Fourth Quarter 2020 12,650,000 $ 0.20 4.50 First Quarter 2021 7,004,908 $ 0.10-0.20 4.75

Organization and Description 24

Organization and Description of Business (Details Narrative) - USD ($)	Dec. 08, 2014	Jun. 30, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Net loss			$ 4,038,648	$ 2,590,645	$ 10,684,051	$ 5,496,051
Cash equivalents			1,399,729		1,399,729
Stockholders equity			$ 6,926,660		$ 6,926,660		$ 5,958,184
Cytocom Inc., [Member]
Number of shares issued druing period	113,242,522						140,100,000
Percentage of stake issued during period	55.30%						41.00%
Irish Limited Liability [Member]
Percentage of low corporate income tax rate		12.50%

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Maximum of annual gross revenue			$ 1,000,000,000
Federal deposit insurance corporation value	$ 250,000
Depreciation expense	981	$ 1,335
Amortization expense	0	148,059
Impairment loss
LDN [Member]
Impairment loss			$ 5,226,352
MENK [Member]
Impairment loss				$ 9,908,477

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Numerator, Net loss	$ (4,038,648)	$ (2,590,645)	$ (10,684,051)	$ (5,496,051)
Numerator, Net loss attributed to Common stockholders	$ (3,928,719)	$ (2,451,754)	$ (10,530,002)	$ (5,233,095)
Denominator, Weighted-average common shares outstanding-Denominator for basic and diluted net loss per share	207,229,469	147,387,763	199,076,428	142,563,007
Denominator, Basic and diluted net loss per share attributed to common stockholders	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.04)

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Summary Of Significant Accounting Policies - Schedule Of Basic And Diluted Net Loss Per Share Details
Warrants to purchase Common stock	32,748,908	9,372,750

Property and Equipment (Details

Property and Equipment (Details Narrative)	6 Months Ended
	Jun. 30, 2016
Property And Equipment Details Narrative
Depreciable asset lives	5 years

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property And Equipment - Schedule Of Property And Equipment Details
Computer equipment	$ 8,013	$ 8,013
Less accumulated depreciation	(7,312)	(6,331)
Property and equipment, net	$ 701	$ 1,682

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accrued Liabilities - Schedule Of Accrued Liabilities Details
Accrued payroll to officers and others	$ 1,013,000	$ 758,000
Accrued interest and penalties - notes payable	843,000	237,000
Accrued legal settlements	174,000	282,000
Other accrued liabilities	1,000	4,000
Total accrued expenses and other liabilities	$ 2,031,000	$ 1,281,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes Payable Details Narrative
Accrued unpaid interest	$ 843,275	$ 236,671
Penalties	$ 581,324	$ 18,954
Issuance of common stock for interest expense,shares	896,296
Issuance of common stock for interest expense	$ 149,000

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Total	$ 3,457,436	$ 2,793,701
Less: Original issue discounts on notes payable and warrants issued with notes	(596,246)
Less: Current portion	(3,457,436)	(2,793,701)
Long-Term debt, less current portion
Notes Payable One [Member]
Total	100,000	100,000
Notes Payable Two [Member]
Total	346,000	711,500
Notes Payable Three [Member]
Total		7,000
Notes Payable Four [Member]
Total	1,033,427	669,933
Notes Payable Five [Member]
Total	200,000	200,000
Notes Payable Six [Member]
Total	775,000	800,000
Notes Payable Seven [Member]
Total	100,000	130,000
Notes Payable Eight [Member]
Total	175,268	175,268
Notes Payable Nine [Member]
Total	1,161,250
Notes Payable Ten [Member]
Total	$ 162,737

Notes Payable - Schedule of N33

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)

Nov. 24, 2015USD ($)shares

Nov. 03, 2015USD ($)shares

Sep. 30, 2015USD ($)shares

Jan. 26, 2015USD ($)shares

Oct. 17, 2014

Jul. 29, 2014

Dec. 31, 2015USD ($)

Jun. 30, 2015USD ($)shares

Sep. 30, 2015USD ($)Installments

Aug. 04, 2016USD ($)

Jun. 30, 2016USD ($)

Apr. 02, 2016USD ($)

Mar. 31, 2016USD ($)

Percentage of interest rate per annum

10.00%

10.00%

10.00%

Maximum amount raise in debt

$ 2,000,000

$ 2,000,000

Number of installments, months | Installments

36

Accrued interest

$ 3,479

$ 8,183

$ 18,828

$ 60,000

Value of notes that converted into shares

$ 50,000

Notes and interest converted into shares | shares

1,069,589

Cytocom Inc., [Member]

Note matures date

Sep. 30, 2016

Value of notes that converted into shares

$ 350,000

Notes and interest converted into shares | shares

4,516,302

Minimum [Member] | Cytocom Inc., [Member]

Percentage of interest rate per annum

5.00%

Maximum [Member] | Cytocom Inc., [Member]

Percentage of interest rate per annum

10.00%

Ira Gaines [Member]

Note matures date

Jan. 27, 2015

Percentage of interest rate per annum

18.00%

Lenders [Member]

Notes aggregating default amount

$ 346,000

Value of notes that converted into shares

$ 278,933

Notes and interest converted into shares | shares

3,722,013

Aggregating loan

$ 834,888

$ 834,888

Interest payable

$ 198,500

$ 198,500

Lenders [Member] | Minimum [Member]

Percentage of interest rate per annum

10.00%

10.00%

Lenders [Member] | Maximum [Member]

Percentage of interest rate per annum

18.00%

18.00%

Roger Bozarth [Member]

Note matures date

Oct. 17, 2015

Percentage of interest rate per annum

2.00%

Lenders [Member]

Notes aggregating default amount

$ 198,500

Robert J. Dailey [Member]

Note matures date

Jul. 30, 2015

Percentage of interest rate per annum

2.00%

Accrued interest

$ 4,778

Notes and interest converted into shares | shares

2,559,725

Lender [Member]

Note matures date

Mar. 9, 2016

Percentage of interest rate per annum

10.00%

Accrued interest

$ 11,304

Pay late-payment penalties per day

$ 5,000

Lender [Member]

Note matures date

Dec. 1, 2016

Percentage of interest rate per annum

10.00%

Value of notes that converted into shares

$ 10,536

Notes and interest converted into shares | shares

1,235,356

Capital Structure - Common St34

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015
Common Stock, Par Value	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000
Common Stock, Shares Issued	214,447,611	174,850,047
Common Stock, Shares Outstanding	214,447,611	174,850,047
Number of warrants issued during period	23,654,908
Warrant maturity date	Dec. 31, 2018
Number of existing warrant issued shares	5,006,666
Warrant Expiry date	Jul. 25, 2016
Warrant extented date	Dec. 17, 2018
Minimum [Member]
Warrant term	3 years
Warrants exercise price per share	$ 0.75
Maximum [Member]
Warrant term	5 years
Warrants exercise price per share	$ 1

Capital Structure - Common St35

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Warrants, Number of shares Beginning balance | shares	9,131,500
Warrants, Number of shares Issued | shares	23,654,908
Warrants, Number of shares Expired | shares	(37,500)
Warrants, Number of shares Exercised | shares	0
Warrants, Number of shares Ending balance | shares	32,748,908
Exercise Price, Expired	$ 5
Exercise Price, Exercised	0
Weighted average exercise price, Beginning balance	1.47
Weighted average exercise price, Issued	0.32
Weighted average exercise price, Expired	5
Weighted average exercise price, Exercised	0
Weighted average exercise price, Ending balance	0.54
Minimum [Member]
Exercise Price, Beginning balance	0.07
Exercise Price, Issued	0.14
Exercise Price, Ending balance	0.07
Maximum [Member]
Exercise Price, Beginning balance	15
Exercise Price, Issued	2
Exercise Price, Ending balance	$ 15

Capital Structure - Common St36

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Third Quarter 2016 [Member]
Number of Shares | shares	125,000
Exercise Price Lower Limit	$ 5
Remaining Life (years)	3 months
Fourth Quarter 2017 [Member]
Number of Shares | shares	350,000
Exercise Price Lower Limit	$ 1.50
Exercise Price Upper Limit	$ 9
Remaining Life (years)	1 year 6 months
First Quarter 2018 [Member]
Number of Shares | shares	127,500
Exercise Price Lower Limit	$ 15
Remaining Life (years)	1 year 9 months
Second Quarter 2018 [Member]
Number of Shares | shares	33,334
Exercise Price Lower Limit	$ 15
Remaining Life (years)	2 years
Third Quarter 2018 [Member]
Number of Shares | shares	250,000
Exercise Price Lower Limit	$ 1.50
Remaining Life (years)	2 years 3 months
Fourth Quarter 2018 [Member]
Number of Shares | shares	6,089,166
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 years 6 months
First Quarter 2019 [Member]
Number of Shares | shares	4,024,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 2
Remaining Life (years)	2 years 9 months
Second Quarter 2019 [Member]
Number of Shares | shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	3 years
Third Quarter 2019 [Member]
Number of Shares | shares	260,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	3 years 3 months
Fourth Quarter 2019 [Member]
Number of Shares | shares	400,000
Exercise Price Lower Limit	$ 0.14
Remaining Life (years)	3 years 6 months
Second Quarter 2020 [Member]
Number of Shares | shares	300,000
Exercise Price Lower Limit	$ 0.50
Remaining Life (years)	4 years
Third Quarter 2020 [Member]
Number of Shares | shares	1,000,000
Exercise Price Lower Limit	$ 0.20
Remaining Life (years)	4 years 3 months
Fourth Quarter 2020 [Member]
Number of Shares | shares	12,650,000
Exercise Price Lower Limit	$ 0.20
Remaining Life (years)	4 years 6 months
First Quarter 2021 [Member]
Number of Shares | shares	7,004,908
Exercise Price Lower Limit	$ 0.10
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	4 years 9 months

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Number of common stock issued for consulting fees	23,643,000	10,239,170
Fair value of common stock	$ 4,543,170	$ 1,810,876
Amortization of prepaid services	$ 1,539,928	$ 3,530,894
Minimum [Member]
Consulting fees amortized period	12 months
Maximum [Member]
Consulting fees amortized period	24 months

Income Taxes - Results of Ope38

Income Taxes - Results of Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2013
Income Taxes - Results Of Operations Details Narrative
Effective tax rate	0.00%	0.00%
Deferred tax assets
Operating loss carryforwards	$ 66,500,000
Operating loss carryforwards expire term	expire in 2032-2035.

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Initial supply, description	Through its wholly-owned subsidiary, TNI BioTech International, Ltd., in December 2015 the Company completed a 90-day bridging trial for the treatment of patients with HIV/AIDS. The trial consisted of a total of 150 patients of both genders between the ages of 18-60, each of whom was infected HIV/AIDS. The primary objective of this bridging trial was to confirm that LodonalTM has a beneficial effect on the immune system of immune deficient patients and that it is safe. The trial separated patients into a Control (placebo) Group and a Treatment Group (which was administered LodonalTM). The efficacy of increasing CD4 count [cell/mm3] between Day-1 and Day-90 by at least 25% was set as the criteria for demonstrating beneficial effect on the immune system. Safety was demonstrated through quality of life assessment and vitals both of which were not adversely affected. Treatment Group patients were given a daily dose of 4.5-mg/kg of Lodonal.
Initial capital to venture	$ 1,000
Percentage of allocated income from venture	25.00%
Orlando, Florida [Member]
Cash rental expense	$ 4,011	$ 18,319
Complete Pharmacy and Medical Solutions, LLC [Member]
Percentage of allocated income from venture	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Aug. 06, 2016

Jul. 19, 2016

Jul. 14, 2016

Jul. 07, 2016

Jul. 02, 2016

Jul. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Aug. 12, 2016

Dec. 31, 2015

Nov. 03, 2015

Sep. 30, 2015

Notes payable

Notes interest rate percentage

10.00%

10.00%

Shares issued for service, shares

23,643,000

10,239,170

Common Stock, Shares Outstanding

214,447,611

174,850,047

Subsequent Event [Member]

Notes payable

$ 100,000

Notes due date

Mar. 29, 2016

Change in notes payable

$ 130,000

Shares issued for service, shares

200,000

1,000,000

Common Stock, Shares Outstanding

220,989,592

Subsequent Event [Member] | Paul Akin [Member]

Notes due date

Jun. 30, 2021

Number of warrants issued

1,000,000

Exercise price of warrant

$ 0.15

Subsequent Event [Member] | Nicholas Plotnikoff [Member]

Notes due date

Jul. 28, 2021

Number of warrants issued

150,000

Exercise price of warrant

$ 0.20

Subsequent Event [Member] | Notes Payable One [Member]

Notes payable

50,000

Interest accrued

$ 3,479

Number of stock issued for debt conversion

1,069,589

Subsequent Event [Member] | Notes Payable Two [Member]

Notes payable

$ 175,267

Interest accrued

$ 10,536

Number of stock issued for debt conversion

1,235,356

Subsequent Event [Member] | Notes Payable Three [Member]

Notes payable

$ 350,000

Interest accrued

$ 11,304

Number of stock issued for debt conversion

4,516,302

Subsequent Event [Member] | Notes Payable Four [Member]

Notes payable

$ 60,000

Interest accrued

$ 8,183

Number of stock issued for debt conversion

852,292

Subsequent Event [Member] | Notes Payable Five [Member]

Notes payable

$ 200,000

Subsequent Event [Member] | Notes Payable Six [Member]

Notes payable

278,933

Subsequent Event [Member] | Notes Payable Five and Six [Member]

Interest accrued

$ 23,606

Number of stock issued for debt conversion

6,281,738

Subsequent Event [Member] | Promissory Notes One [Member]

Notes payable

$ 50,000

Notes due date

Oct. 5, 2016

Notes interest rate percentage

6.00%

Subsequent Event [Member] | Promissory Notes Two [Member]

Notes payable

$ 180,000

Notes due date

Mar. 7, 2017

Notes interest rate percentage

15.00%

Proceeds fom notes payable

$ 150,000

Convertible threshold percentage

80.00%

Subsequent Event [Member] | Minimum [Member]

Interest accrued

$ 100,000

Subsequent Event [Member] | Maximum [Member]

Interest accrued

$ 225,000